Filter Results:
(611)
Show Results For
- All HBS Web
(1,022)
- People (4)
- News (256)
- Research (611)
- Events (9)
- Multimedia (24)
- Faculty Publications (396)
Show Results For
- All HBS Web
(1,022)
- People (4)
- News (256)
- Research (611)
- Events (9)
- Multimedia (24)
- Faculty Publications (396)
Sort by
- 15 Dec 2014
- Research & Ideas
Deconstructing the Price Tag
expenses incurred. For example, R&D expenditures in the pharmaceutical industry involve more than just the cost of producing one particular drug. Many drugs may have to fail before one succeeds, and that one hit View Details
- 25 May 2016
- Research & Ideas
How Consumers and Businesses are Reshaping Public Health
commercialization of important new drugs to the detriment of consumers. Interestingly, though, at public hearings, the AstraZeneca chief executive championed the interests of patients in opposing the proposed merger. Consumers worldwide... View Details
- 19 Sep 2012
- Research & Ideas
Funding Innovation: Is Your Firm Doing it Wrong?
programs to an investment board comprising both insiders (senior GSK executives) and outsiders (including a venture capitalist and a biotech CEO). After a three-month review period, successful teams are awarded three years worth of investment funding. Because View Details
Keywords: by Carmen Nobel
- 20 May 2016
- Op-Ed
World Health Organization Lacks Leadership to Combat Pandemics
greater role in WHO governance and if there are guarantees of purchase contracts for new drugs and vaccines at sensible prices. Both seem unlikely, as the WHO's culture has always winced at cooperation with the private sector. WHO's track... View Details
- 14 Jul 2006
- Op-Ed
The Case for Consumer-Driven Medicaid
diabetic and asthmatic enrollees due to increased testing and drug utilization, while management consulting firm McKinsey found that consumer-driven enrollees were more likely to "very carefully follow treatment regimens for chronic... View Details
Keywords: by Regina E. Herzlinger
- 27 Aug 2008
- Research & Ideas
Creating Leaders for Science-Based Businesses
Ph.D. in biology and a former biology professor at Harvard, has also had a 25-year career in drug development and biotech companies, leading both R&D and business functions. She teaches the MBA elective Inventing Breakthroughs and... View Details
- 30 Jun 2003
- Research & Ideas
Computer Security is For Managers, Too
each warrants. A bank, for instance, might assign the greatest amount of protection to the database that stores its customers' financial information. For a pharmaceutical company, it might be the research servers that hold data on promising View Details
- 26 Apr 2004
- Research & Ideas
A Clear Eye for Innovation
series of contact-lens products, introduced a drug for treating age-related macular degeneration, pioneered a new lens-manufacturing process that dramatically reduced production costs, and overtook J&J in some market segments. The... View Details
- 15 Feb 2000
- Lessons from the Classroom
Delivering Information Services: A 30-Year Perspective
IPO in 1990 to a $10-billion company today, with a market value of close to $140 billion! I'm also doing research for a case on Drugstore.com, which is essentially a drug store "built" on the Internet. It's getting ready to... View Details
Keywords: by Staff
- 18 Apr 2017
- First Look
First Look at New Ideas, April 18
M&A) and Werner Baumann (CFO) have to decide whether to increase the cash portion of their $14.2 billion offer and/or amend the terms of a proposed joint venture (JV) with Merck involving cardiovascular drugs that had been included in... View Details
Keywords: by Sean Silverthorne
- 15 Jun 2016
- Research & Ideas
These VC Partners May Make Your Firm Less Innovative
developed by the Food and Drug Administration (FDA), they were able to tell which companies were competitors in the same patient application areas (such as cardiology, oncology, or urology) and product classes. Then, using commercial... View Details
- 25 Aug 2015
- First Look
First Look Tuesday
to examine the phenomena in the context of health. In particular, we examine how an individual's prior experiences and the experiences of those around them alter the operational decisions that the individual makes. We draw on an exogenous announcement of negative news... View Details
- 05 Nov 2007
- Research & Ideas
The Changing Face of American Innovation
on? Are they concentrated in a specific industry or business type? A: Inventors can file for patents in many technology fields, ranging from chemicals and drugs to computer software to agricultural machinery. Immigrant contributions are... View Details
- 11 May 2010
- First Look
First Look: May 11
rapid evolution of the biopharmaceutical industry. In the early 2000s, as Millennium's competitive advantage in early-stage research slipped away and its losses mounted, founder and CEO Mark Levin moved the firm downstream away from research and towards View Details
Keywords: Martha Lagace
- 13 Jul 2009
- Research & Ideas
Diagnosing the Public Health Care Alternative
of its inadequate payments. In the end, the Democrats' health care reform will require drastic rationing of health care for the sick to control its costs. The government-controlled UK health care system points the way because it features, for example, the lowest uptake... View Details
- 25 Oct 2016
- First Look
October 25, 2016
insulate consumers from cost sharing, thereby undermining insurers’ ability to influence drug utilization. We study the impact of copay coupons on branded drugs first facing generic entry between 2007 and... View Details
Keywords: Sean Silverthorne
- 07 Aug 2007
- First Look
First Look: August 7, 2007
and issues around current practices. Purchase this note: http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=807124 U.S. Food and Drug Administration Harvard Business School Note 807-050 Describes the U.S. FDA with particular... View Details
Keywords: Martha Lagace
- 07 Aug 2006
- Research & Ideas
Whatever Happened to Caveat Emptor?
basic material needs to concerns about the safety and quality of these products. When products did fail—as happened dramatically in the late 1950s with the antinausea drug Thalidomide—such cases became the focus of aggressive consumer... View Details
- 06 May 2008
- First Look
First Look: May 6, 2008
Fibrosis Foundation: Venture Philanthropy Funding for Biotech Harvard Business School Case 808-005 In 2001, Vertex Pharmaceuticals Incorporated acquired the San Diego-based biotech company, Aurora Biosciences. The combination of Vertex's and Aurora's technologies would... View Details
Keywords: Martha Lagace
- 19 Jun 2012
- First Look
First Look: June 19
312-002 McKesson, a large, diversified drug distribution and health care IT company, is considering development of new business offerings to help private practice physicians remain independent. The company, with $122 billion in 2010... View Details
Keywords: Sean Silverthorne